(redirected from JAK2 mutation)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to JAK2 mutation: myelofibrosis, polycythemia, polycythemia vera

MUTATION, French law. This term is synonymous with change, and is particularly applied to designate the change which takes place in the property of a thing in its transmission from one person to another; permutation therefore happens when, the owner of the thing sells, exchanges or gives it. It is nearly synonymous with transfer. (q.v.) Merl. Repert. h.t.

A Law Dictionary, Adapted to the Constitution and Laws of the United States. By John Bouvier. Published 1856.
References in periodicals archive ?
The JAK2 mutation also occurs in CMML patients sharing some mutual features with [JAK2.sup.mut] MPNs.
September 2016: Bone marrow biopsy comments: Chronic lymphocytic leukemia (10% involvement); JAK2 mutation positive, marked reticulin fibrosis, consistent with myeloproliferative neoplasm, such as primary myelofibrosis.
(15) Myeloproliferative disorders (MPD) is also a common risk factor for PVT.3 A meta-analysis showed that the mean prevalence of MPD and JAK2 mutation was 31.5% (95% CI: 25.1-38.8%) and 27.7% (95% CI: 20.8-35.8), respectively.
(2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Gharibyan et al., "JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia," Blood, vol.
JAK2 mutation was seen in 64/93 (69%) patients including 33/33(100%) in PV, 19/36(52.6%) in ET and 12/24(50%) in IMF.
Additional work up revealed a JAK2 mutation and a heterozygous factor V Leiden mutation.
JAK2 mutation has been shown to be associated with a wide spectrum of chronic myeloproliferative disorders (5-9).
The team found that 16 of 81 samples from patients with Down syndrome had the JAK2 mutation. The defect was exceptionally rare in ALL patients without Down syndrome.
Coverage includes techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP 1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of acute myeloid leukemia by DNA- oligonucleotide microarrays, detection of the V617F JAK2 mutation in myeloproliferative disorders, gene rearrangements, FLT3 mutations andWT-1 overexpression.
This patient expressed PD-L1/2 and JAK2 mutation. PD-1, an immune checkpoint receptor expressed by T-cells, binds to its ligands and suppresses antigen-specific cancer immune reactions.